GH 56
Alternative Names: GH-56Latest Information Update: 12 Jun 2024
At a glance
- Originator Suzhou Genhouse Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Jun 2024 Preclinical trials in Cancer in China (unspecified route) (Suzhou Genhouse Bio pipeline, June 2024)
- 11 Jun 2024 Preclinical trials in Cancer in China (unspecified route) (Suzhou Genhouse Bio pipeline, June 2024)
- 05 Apr 2024 Pharmacodynamics and adverse events data from preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)